{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:38:27Z","timestamp":1767991107686,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40801-021-00242-x","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T14:03:03Z","timestamp":1615816983000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986\u20132019"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-5897","authenticated-orcid":false,"given":"Shaokui","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-2118","authenticated-orcid":false,"given":"Manette T.","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-2935","authenticated-orcid":false,"given":"Gra\u00e7a M.","family":"Dores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"242_CR1","unstructured":"U.S. Food and Drug Administration. DigiFab (Digoxin Immune Fab [Ovine]). https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/digifab. Accessed 20 July 2020."},{"issue":"1","key":"242_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1073\/pnas.57.1.71","volume":"57","author":"VP Butler Jr","year":"1967","unstructured":"Butler VP Jr, Chen JP. Digoxin-specific antibodies. Proc Natl Acad Sci USA. 1967;57(1):71\u20138. https:\/\/doi.org\/10.1073\/pnas.57.1.71.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"242_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJM197604082941501","volume":"294","author":"TW Smith","year":"1976","unstructured":"Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294(15):797\u2013800. https:\/\/doi.org\/10.1056\/NEJM197604082941501.","journal-title":"N Engl J Med."},{"issue":"10","key":"242_CR4","first-page":"587","volume":"110","author":"TH Schaeffer","year":"2010","unstructured":"Schaeffer TH, Mlynarchek SL, Stanford CF, Delgado J, Holstege CP, Olsen D, et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab\u2014a retrospective study. J Am Osteopath Assoc. 2010;110(10):587\u201392.","journal-title":"J Am Osteopath Assoc."},{"issue":"5","key":"242_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00007691-200010000-00016","volume":"22","author":"SB Ward","year":"2000","unstructured":"Ward SB, Sjostrom L, Ujhelyi MR. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther Drug Monit. 2000;22(5):599\u2013607. https:\/\/doi.org\/10.1097\/00007691-200010000-00016.","journal-title":"Ther Drug Monit."},{"issue":"21","key":"242_CR6","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"DS Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002\u201312. https:\/\/doi.org\/10.1056\/NEJMsa1103053.","journal-title":"N Engl J Med."},{"issue":"8","key":"242_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3109\/15563650.2014.943907","volume":"52","author":"BS Chan","year":"2014","unstructured":"Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52(8):824\u201336. https:\/\/doi.org\/10.3109\/15563650.2014.943907.","journal-title":"Clin Toxicol (Phila)."},{"key":"242_CR8","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s adverse event reporting system. https:\/\/www.fda.gov\/drugs\/surveillance\/fda-adverse-event-reporting-system-faers. Accessed 26 May 2020."},{"key":"242_CR9","unstructured":"MedDRA. Introductory Guide: MedDRA version 20.1. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_20_1_english_0.pdf. Published September 2017. Accessed 21 May 2020."},{"issue":"1","key":"242_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377. https:\/\/doi.org\/10.1007\/s40264-013-0131-x.","journal-title":"Drug Saf."},{"key":"242_CR11","unstructured":"US Government Publishing Office. Postmarketing reporting of adverse experiences. 21 CFR section 600.80. https:\/\/www.govinfo.gov\/app\/details\/CFR-2018-title21-vol7\/CFR-2018-title21-vol7-sec600-80. Published April 1, 2018. Accessed 18 July 2020."},{"issue":"6","key":"242_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.26.6.748","volume":"26","author":"A Szarfman","year":"2006","unstructured":"Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006;26(6):748\u201358. https:\/\/doi.org\/10.1592\/phco.26.6.748.","journal-title":"Pharmacotherapy"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u201390.","journal-title":"Am Stat"},{"issue":"6","key":"242_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf."},{"key":"242_CR15","unstructured":"Office of the Federal Register and the Government Publishing Office. Electronic Code of Federal Regulations. https:\/\/www.ecfr.gov\/cgi-bin\/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML#se45.1.46_1104. Accessed 25 May 2020."},{"issue":"5","key":"242_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jchf.2015.12.003","volume":"4","author":"N Patel","year":"2016","unstructured":"Patel N, Ju C, Macon C, Thadani U, Schulte PJ, Hernandez AF, et al. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC Heart Fail. 2016;4(5):348\u201356. https:\/\/doi.org\/10.1016\/j.jchf.2015.12.003.","journal-title":"JACC Heart Fail."},{"issue":"5","key":"242_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jchf.2016.01.011","volume":"4","author":"PJ Hauptman","year":"2016","unstructured":"Hauptman PJ, Blume SW, Lewis EF, Ward S. Digoxin toxicity and use of digoxin immune fab: insights from a national hospital database. JACC Heart Fail. 2016;4(5):357\u201364. https:\/\/doi.org\/10.1016\/j.jchf.2016.01.011.","journal-title":"JACC Heart Fail."},{"issue":"6","key":"242_CR18","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1161\/01.cir.81.6.1744","volume":"81","author":"EM Antman","year":"1990","unstructured":"Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744\u201352. https:\/\/doi.org\/10.1161\/01.cir.81.6.1744.","journal-title":"Circulation"},{"issue":"3","key":"242_CR19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/s0735-1097(10)80170-6","volume":"17","author":"AR Hickey","year":"1991","unstructured":"Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590\u20138. https:\/\/doi.org\/10.1016\/s0735-1097(10)80170-6.","journal-title":"J Am Coll Cardiol."},{"issue":"4\u20136","key":"242_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/15563658508990641","volume":"23","author":"A Smolarz","year":"1985","unstructured":"Smolarz A, Roesch E, Lenz E, Neubert H, Abshagen P. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol. 1985;23(4\u20136):327\u201340. https:\/\/doi.org\/10.3109\/15563658508990641.","journal-title":"J Toxicol Clin Toxicol."},{"issue":"4","key":"242_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/0003-4819-119-4-199308150-00004","volume":"119","author":"MR Ujhelyi","year":"1993","unstructured":"Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Green PJ, Sailstad J, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993;119(4):273\u20137. https:\/\/doi.org\/10.7326\/0003-4819-119-4-199308150-00004.","journal-title":"Ann Intern Med."},{"issue":"4","key":"242_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1046\/j.1365-3156.1999.00397.x","volume":"4","author":"M Eddleston","year":"1999","unstructured":"Eddleston M, Ariaratnam CA, Meyer WP, Perera G, Kularatne AM, Attapattu S, et al. Epidemic of self-poisoning with seeds of the yellow oleander tree (Thevetia peruviana) in northern Sri Lanka. Trop Med Int Health. 1999;4(4):266\u201373. https:\/\/doi.org\/10.1046\/j.1365-3156.1999.00397.x.","journal-title":"Trop Med Int Health."},{"issue":"4","key":"242_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jemermed.2018.05.021","volume":"55","author":"ME Wermuth","year":"2018","unstructured":"Wermuth ME, Vohra R, Bowman N, Furbee RB, Rusyniak DE. Cardiac toxicity from intentional ingestion of pong-pong seeds (Cerbera odollam). J Emerg Med. 2018;55(4):507\u201311. https:\/\/doi.org\/10.1016\/j.jemermed.2018.05.021.","journal-title":"J Emerg Med."},{"issue":"7","key":"242_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s0196-0644(88)80625-5","volume":"17","author":"GM Shumaik","year":"1988","unstructured":"Shumaik GM, Wu AW, Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med. 1988;17(7):732\u20135. https:\/\/doi.org\/10.1016\/s0196-0644(88)80625-5.","journal-title":"Ann Emerg Med."},{"issue":"5","key":"242_CR25","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1378\/chest.110.5.1282","volume":"110","author":"JR Brubacher","year":"1996","unstructured":"Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest. 1996;110(5):1282\u20138. https:\/\/doi.org\/10.1378\/chest.110.5.1282.","journal-title":"Chest"},{"issue":"1","key":"242_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0009-8981(01)00499-5","volume":"309","author":"A Dasgupta","year":"2001","unstructured":"Dasgupta A, Lopez AE, Wells A, Olsen M, Actor J. The Fab fragment of anti-digoxin antibody (digibind) binds digitoxin-like immunoreactive components of Chinese medicine Chan Su: monitoring the effect by measuring free digitoxin. Clin Chim Acta. 2001;309(1):91\u20135. https:\/\/doi.org\/10.1016\/s0009-8981(01)00499-5.","journal-title":"Clin Chim Acta."},{"issue":"2","key":"242_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1309\/93UF-4YEL-EMG9-V548","volume":"121","author":"A Dasgupta","year":"2004","unstructured":"Dasgupta A, Szelei-Stevens KA. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol. 2004;121(2):276\u201381. https:\/\/doi.org\/10.1309\/93UF-4YEL-EMG9-V548.","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"242_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0196-0644(05)82138-9","volume":"19","author":"RO Cummins","year":"1990","unstructured":"Cummins RO, Haulman J, Quan L, Graves JR, Peterson D, Horan S. Near-fatal yew berry intoxication treated with external cardiac pacing and digoxin-specific FAB antibody fragments. Ann Emerg Med. 1990;19(1):38\u201343. https:\/\/doi.org\/10.1016\/s0196-0644(05)82138-9.","journal-title":"Ann Emerg Med."},{"issue":"6","key":"242_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1060028017754225","volume":"52","author":"AW Labossiere","year":"2018","unstructured":"Labossiere AW, Thompson DF. Clinical toxicology of yew poisoning. Ann Pharmacother. 2018;52(6):591\u20139. https:\/\/doi.org\/10.1177\/1060028017754225.","journal-title":"Ann Pharmacother."},{"issue":"7","key":"242_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761\u20137. https:\/\/doi.org\/10.1080\/14740338.2017.1323867.","journal-title":"Expert Opin Drug Saf."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-021-00242-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00242-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:50:59Z","timestamp":1724633459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-021-00242-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s40801-021-00242-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"28 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors do not have any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SW had full access to the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: SW. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: SW and GMD (data mining). Supervision: GMD. Note: The opinions and information in this article are those of the authors and do not represent the views or policies of the US Food and Drug Administration.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}